Suppr超能文献

人类感染大肠杆菌O157:H7

Escherichia coli O157:H7 infection in humans.

作者信息

Su C, Brandt L J

机构信息

Montefiore Medical Center, Bronx, New York, USA.

出版信息

Ann Intern Med. 1995 Nov 1;123(9):698-714. doi: 10.7326/0003-4819-123-9-199511010-00009.

Abstract

OBJECTIVE

To review the clinical relevance of Escherichia coli O157:H7 infection, including the epidemiology of the infection and its clinical presentations, pathogenesis, microbiology, diagnosis, treatment, and prevention.

DATA SOURCES

Articles on E. coli O157:H7 were identified through MEDLINE and the bibliographies of relevant articles.

STUDY SELECTION

All articles and case reports describing E. coli O157:H7 and its infection were selected.

DATA EXTRACTION

The data were abstracted without judgments about study design. Data quality and validity were assessed by independent author reviews.

DATA SYNTHESIS

Infection with E. coli O157:H7 presents with a wide spectrum of clinical manifestations, including asymptomatic carriage, nonbloody diarrhea, hemorrhagic colitis, the hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura. Not only is E. coli O157:H7 an important agent for hemorrhagic colitis, it is also one of the leading causes of bacterial diarrhea. Patients at extremes of age have an increased risk for infection and associated complications. Transmission of E. coli O157:H7 is primarily food-borne. Undercooked meat is the most common culprit, and secondary person-to-person spread is also important. The organism produces at least two Shiga-like toxins that differ antigenically, physicochemically, immunologically, and in their biological effects. These toxins are thought to have direct pathogenic significance in E. coli O157:H7 infection. This infection is usually diagnosed from a positive stool culture, from the presence of Shiga-like toxins, or both. Timely collection (within 7 days of illness onset) of a stool sample for culture is imperative for a high recovery rate. Treatment is primarily supportive and includes the management of complications as necessary. Antibiotic therapy has not been proved beneficial. Important public health measures include educating the public on the danger of eating undercooked meat, increasing physician awareness of E. coli O157:H7 infection, and mandating case reporting.

CONCLUSIONS

Infection with E. coli O157:H7 presents with many clinical manifestations and should be included in the differential diagnosis for any patient with new-onset bloody diarrhea. Development of the hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura should raise strong suspicion of E. coli O157:H7 infection and should lead to prompt evaluation. If infection is confirmed, it should be reported to public health officials.

摘要

目的

综述大肠埃希菌O157:H7感染的临床相关性,包括感染的流行病学、临床表现、发病机制、微生物学、诊断、治疗及预防。

资料来源

通过医学文献数据库(MEDLINE)及相关文章的参考文献检索有关大肠埃希菌O157:H7的文章。

研究选择

选取所有描述大肠埃希菌O157:H7及其感染的文章和病例报告。

资料提取

提取数据时不对研究设计作判断。数据质量和有效性由独立作者审查评估。

资料综合

大肠埃希菌O157:H7感染有广泛的临床表现,包括无症状携带、非血性腹泻、出血性结肠炎、溶血尿毒综合征及血栓性血小板减少性紫癜。大肠埃希菌O157:H7不仅是出血性结肠炎的重要病原体,也是细菌性腹泻的主要病因之一。年龄极端者感染及相关并发症的风险增加。大肠埃希菌O157:H7主要通过食物传播。未煮熟的肉类是最常见的罪魁祸首,其次人与人之间的传播也很重要。该菌产生至少两种志贺样毒素,它们在抗原性、理化性质、免疫学及生物学效应方面存在差异。这些毒素被认为在大肠埃希菌O157:H7感染中具有直接致病意义。该感染通常通过粪便培养阳性、志贺样毒素的存在或两者来诊断。为获得高回收率,必须在发病7天内及时采集粪便样本进行培养。治疗主要是支持性的,必要时包括并发症的处理。抗生素治疗尚未被证明有益。重要的公共卫生措施包括对公众进行食用未煮熟肉类危险性的教育、提高医生对大肠埃希菌O157:H7感染的认识以及强制要求病例报告。

结论

大肠埃希菌O157:H7感染有多种临床表现,对于任何新发血性腹泻患者均应列入鉴别诊断。溶血尿毒综合征或血栓性血小板减少性紫癜的发生应高度怀疑大肠埃希菌O157:H7感染,并应迅速进行评估。如果感染得到确诊,应向公共卫生官员报告。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验